VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma

Malignant mesotheliomas frequently harbor loss of CDK2NA which is associated with shorter survival and may represent a novel treatment strategy for these patients. Dean A. Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, presents findings of a Phase II study investigating the efficacy of abemaciclib, a CDK4/6 inhibitor in patients with p16ink4a negative relapsed mesothelioma in the MiST2 study (NCT03654833). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter